2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-168520
    NLRP3-IN-57 98%
    NLRP3-IN-57 (compound 5) inhibits the NLRP3 inflammasome, thereby reducing IL-1β levels in LPS plus Nigericin-induced THP-1 macrophages..
    NLRP3-IN-57
  • HY-168539
    TM11 98%
    TM11, a Tanshinone mimic, is a potent HuR inhibitor that can inhibit HuR-RNA complex formation. TM11 reduces LPS-induced inflammatory response in murine macrophages.
    TM11
  • HY-168561
    NLRP3-IN-58 2956014-05-2 98%
    NLRP3-IN-58 (Compound DS15) is an inhibitor for the activation of NLRP3 inflammasome with an IC50 of 3.85 μM, and inhibits 33% IL-1β release at a concentration of 10 μM.
    NLRP3-IN-58
  • HY-168766
    O-Acetylsalicylhydroxamic acid 199854-00-7 98%
    O-Acetylsalicylhydroxamic acid is an acetylation inhibitor of prostaglandin H2 synthase that can suppress PGE2 synthesis in the body and block the cyclooxygenase activity of PGHS in vitro. O-Acetylsalicylhydroxamic acid requires the presence of the active site residue Ser-529 to act on human PGHS-1; the S529A mutant is resistant to the inactivation effects of this inhibitor.
    O-Acetylsalicylhydroxamic acid
  • HY-168782
    Resolvin D2 n-3 DPA 2093111-29-4 98%
    Resolvin D2 n-3 DPA is a specialized proresolving mediator (SPM). Resolvin D2 n-3 DPA (1 nM) can reduce the chemotaxis and adhesion of human neutrophils induced by TNF-α. Resolvin D2 n-3 DPA (100 ng/mouse; intravenous injection) can reduce neutrophil infiltration in the peritoneum and the levels of IL-6 and the chemokine (C-C motif) ligand 2 (CCL2) in a mouse model of inflammation induced by zinc oxide.
    Resolvin D2 n-3 DPA
  • HY-168784
    LTD4 antagonist 2 107813-86-5 98%
    LTD4 antagonist 2 (compound 6) is a leukotriene D4 (LTD4) antagonist with an IC50 of 2.8 μM against cysteinyl leukotriene 1 receptor (CysLT1R). LTD4 antagonist 2 is also a G protein-coupled bile acid receptor 1 (GPBAR1) agonist and can be utilized in research related to colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases.
    LTD4 antagonist 2
  • HY-168906
    BI-113823 1119282-90-4 98%
    BI-113823 is an orally active and selective bradykinin B1 receptor antagonist. BI-113823 can reduce complete Freund's adjuvant (HY-153808)-induced mechanical hyperalgesia in rats. BI-113823 can be used for the research of chronic inflammatory pain.
    BI-113823
  • HY-168955
    Antibacterial agent 269 98%
    Antibacterial agent 269 (3.8) is an inhibitor of AdeG Efflux Pumps in Acinetobacter baumannii.
    Antibacterial agent 269
  • HY-169132
    Anti-MRSA agent 17 98%
    Anti-MRSA agent 17 (8) is an inhibitor against S. aureus (MRSA) BPL (SaBPL), with a Ki of 10.3 nM.
    Anti-MRSA agent 17
  • HY-169536
    CFTR activator 2 871700-29-7 99.54%
    CFTR activator 2 (WAY-326769) is an activator of mutant cystic fibrosis transmembrane conductance regulator (mutant-CFTR).
    CFTR activator 2
  • HY-169555
    ASK1-IN-7 1427537-92-5 98%
    ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. ASK1-IN-7 holds promise for research related to the ASK1 signaling pathway, such as cell stress responses, inflammation, neurodegenerative diseases, and cardiovascular diseases.
    ASK1-IN-7
  • HY-169602
    GSK-3β inhibitor 26 70169-39-0 98%
    GSK-3β inhibitor 26 (Compound D14) is a GSK-3β inhibitor with an IC50 of 18.23 μM. GSK-3β inhibitor 26 can be used in the research of cancer, inflammation and neurodegenerative diseases.
    GSK-3β inhibitor 26
  • HY-169674
    JNK-IN-20 346663-56-7 98%
    JNK-IN-20 (compound 5) is a JNK inhibitor. JNK-IN-20 can be used in inflammation and tumor related research.
    JNK-IN-20
  • HY-169678
    GRK6-IN-5 33495-39-5 98%
    GRK6-IN-5 is a GRK6 polypeptide inhibitor, with IC50 value of 4.48 μΜ. GRK6-IN-5 can be used to study hematological malignancies, inflammation diseases, and autoimmune disorders.
    GRK6-IN-5
  • HY-169685
    p38 MAPK-IN-6 421578-44-1 98%
    p38 MAPK-IN-6 (compound c47) is a p38 MAPK inhibitor. p38 MAPK-IN-6 shows 14% inhibition at 10 μM.
    p38 MAPK-IN-6
  • HY-169758
    CEE321 2098545-89-0 98%
    CEE321 is a potent pan-JAK inhibitor with an IC50 value of 54 nM. CEE321 potently inhibits biomarkers associated with atopic dermatitis.
    CEE321
  • HY-169780
    (S)-AMG-628 862269-92-9 98%
    (S)-AMG-628 (Compound 16q) is the S-isomer of AMG-628 (HY-123374). (S)-AMG-628 is the orally active antagonist for TRPV1, that inhibits the Capsaicin (HY-10448)- and acid-induced Ca2+-influx with IC50 of 7 nM and 5 nM in CHO cell. (S)-AMG-628 ameliorates Capsaicin-induced rats flinching, and reverses the thermal hypersensitivity in CFA-(HY-153808) induced inflammatory pain models.
    (S)-AMG-628
  • HY-169817
    PAR-2-IN-2 313986-65-1 98%
    PAR-2-IN-2 (compound P-596) is a protease-activated receptor 2 (PAR-2) inhibitor with an IC50 of 10.79 μM for SLIGKV and an IC50 of greater than 200 μM for Trypsin.
    PAR-2-IN-2
  • HY-169819
    Calcium influx inducer compound 634 882291-37-4 98%
    Calcium influx inducer compound 634 is a calcium influx inducer. Calcium influx inducer compound 634 (10 µM) enhances the release of extracellular vesicles (EVs) from mouse bone marrow-derived dendritic cells (mBMDCs). Calcium influx inducer compound 634 (10 µM) also increases the levels of CD86 and CD80 on the surface of mBMDCs, an effect that can be blocked by the calcium release-activated calcium channel inhibitor YM-58483 (HY-100831).
    Calcium influx inducer compound 634
  • HY-169853
    M351-0056 1189495-81-5 98%
    M351-0056 is the agonist for the immune checkpoint protein VISTA, that reduces the secretion of VISTA-induced cytokines, promotes the T-cell proliferation induced by VISTA, and exhibits immunomodulatory activity. M351-0056 ameliorates Imiquimod (HY-B0180)-induced psoriatic dermatitis in mouse models.
    M351-0056
Cat. No. Product Name / Synonyms Application Reactivity